Related Experiment Video

Updated: Jun 7, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K

The future of hypertension pharmacotherapy: Ongoing and future clinical trials for hypertension

Taha Mansoor1, Fatima Farrukh2, Subaina N Khalid3

  • 1Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.

Current Problems in Cardiology
|November 10, 2024
PubMed

Insights

This review summarizes ongoing clinical trials for hypertension treatments. It highlights novel pharmacological and dietary therapies under investigation to manage high blood pressure and reduce associated health risks.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Pharmacology
  • Public Health

Background:

  • Hypertension is a global health issue, significantly increasing the risk of stroke, heart disease, and kidney disease.
  • Current pharmacological treatments for hypertension target mechanisms like vasodilation, renin-angiotensin-aldosterone pathway inhibition, and blood volume reduction.
  • Continuous research is essential to discover novel therapeutic pathways for hypertension management.

Purpose of the Study:

  • To review ongoing clinical trials for pharmacological hypertension therapies.
  • To identify emerging trends and future directions in hypertension treatment based on current research.
  • To provide insights into novel pharmacological and dietary supplement interventions for hypertension.

Main Methods:

  • A systematic search of clinicaltrials.gov was conducted in March 2024.
  • Identified 103 clinical trials meeting specific criteria for pharmacological hypertension therapy.
  • Included trials investigating both novel and approved pharmacological agents and dietary supplements.

Main Results:

  • 103 clinical trials focusing on pharmacological hypertension treatments were identified.
  • Interventions encompass a range of novel and established drug therapies.
  • Dietary supplements are also being explored as potential hypertension treatments.

Conclusions:

  • The landscape of hypertension treatment is evolving with numerous ongoing clinical investigations.
  • Future hypertension management may involve a broader spectrum of pharmacological and dietary interventions.
  • This review offers a snapshot of current research, guiding future therapeutic strategies.

Keywords:
Clinical trialsfuturehypertensionpharmacotherapy

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

675
Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.1K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135